DURHAM, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix, will present a corporate overview at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant unmet medical needs.
Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
ir@chimerix.com
or
Will O'Connor
Stern Investor Relations
Will@sternir.com
212-362-1200
Media:
Becky Vonsiatsky
W2O Groupbvonsiatsky@w2ogroup.com
413-478-2003
Source:
Chimerix, Inc.
News Provided by Acquire Media
